The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide
Open accessAbstract
Cyclophosphamide (Cy) is a potent immunosuppressive agent that is selectively toxic to lymphocytes proliferating in response to recent antigen stimulation. In animal models, both graft rejection and GVHD after histoincompatible BMT can be inhibited by the posttransplantation administration of high-dose Cy. Therefore, a phase I clinical trial was undertaken to determine the minimal conditioning, including posttransplantation Cy, that permits the stable engraftment of partially HLA-mismatched marrow (up to 3 HLA antigens) from first-degree relatives. Thirteen patients (median age, 53 years) with high-risk hematologic malignancies received conditioning with fludarabine, 30 mg/m2 per day from days -6 to -2, and TBI, 2 Gy on day -1. All patients received Cy, 50 mg/kg on day 3, mycophenolate mofetil from day 4 to day 35, and tacrolimus from day 4 to day > or = 50. Three patients in cohort 1 received no additional conditioning, and 2 experienced graft rejection. Ten patients in cohort 2 received identical conditioning with the addition of Cy 14.5 mg/kg on days -6 and -5. Sustained donor cell engraftment occurred in 8 of these patients, with a median time to absolute neutrophil count > 500/microL of 15 days (range, 13-16 days) and to unsupported platelet count > 20,000/microL of 14 days (range, 0-26 days). All patients with engraftment achieved > or = 95% donor chimerism within 60 days of transplantation. Two patients with myelodysplastic syndrome rejected their grafts but experienced autologous neutrophil recovery at 24 and 44 days. Histologic acute GVHD developed in 6 patients (grade II in 3 patients, grade III in 3 patients) at a median of 99 days (range, 38-143 days) after transplantation and was fatal in 1 patient. At a median follow-up of 191 days (range, 124-423 days), 6 of 10 patients in cohort 2 were alive, and 5 were in complete remission of their disease, including both patients with graft rejection. These data demonstrate that partially HLA-mismatched bone marrow can engraft rapidly and stably after nonmyeloablative conditioning that includes posttransplantation Cy. Clinically significant antitumor responses occur, even among patients who reject their donor grafts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1994 Consensus Conference on Acute GVHD Grading.
Przepiorka, D., Weisdorf, D., Martin, P., Hg, K., Beatty, P., Hows, J., & Thomas, E. D. (1995) · PubMed · Cited by 5,037
Clues to the Pathogenesis of Familial Colorectal Cancer
Aaltonen, L. A., Peltomäki, P., Leach, F. S., Sistonen, P., Pylkkänen, L., Mecklin, J.-P., Järvinen, H., Powell, S. M., Jen, J., Hamilton, S. R., et al. (1993) · Science · doi:10.1126/science.8484121 · Cited by 2,710
McSweeney, P. A., Niederwieser, D., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., Maloney, D. G., Chauncey, T. R., Gooley, T. A., Hegenbart, U., Nash, R. A., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3390 · Cited by 1,389
Aversa, F., Tabilio, A., Velardi, A., Cunningham, I., Terenzi, A., Falzetti, F., Ruggeri, L., Barbabietola, G., Aristei, C., Latini, P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810223391702 · Cited by 1,168
Giralt, S., Estey, E., Albitar, M., van Besien, K., Rondón, G., Anderlini, P., O'Brien, S., Khouri, I., Gajewski, J., Mehra, R., et al. (1997) · Blood · doi:10.1182/blood.v89.12.4531 · Cited by 1,138
Marrow Transplantation from Related Donors Other Than HLA-Identical Siblings
Beatty, P. G., Clift, R. A., Mickelson, E. M., Nisperos, B. B., Flournoy, N., Martin, P. J., Sanders, J. E., Stewart, P., Buckner, C. D., Storb, R., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198509263131301 · Cited by 816
Anasetti, C., Amos, D., Beatty, P. G., Appelbaum, F. R., Bensinger, W., Buckner, C. D., Clift, R., Doney, K., Martin, P. J., Mickelson, E., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198901263200401 · Cited by 674
Bone Marrow Transplantation for Sickle Cell Disease
Walters, M. C., Patience, M., Leisenring, W., Eckman, J. R., Scott, J. P., Mentzer, W. C., Davies, S. C., Ohene-Frempong, K., Bernaudin, F., Matthews, D. C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608083350601 · Cited by 627
Childs, R., Clave, E., Contentin, N., Jayasekera, D., Hensel, N., Leitman, S., Read, E. J., Carter, C., Bahceci, E., Young, N. S., et al. (1999) · Blood · doi:10.1182/blood.v94.9.3234 · Cited by 526
Champlin, R. E., Schmitz, N., Horowitz, M. M., Chapuis, B., Chopra, R., Cornelissen, J. J., Gale, R. P., Goldman, J. M., Loberiza, F. R., Hertenstein, B., et al. (2000) · PubMed · doi:10.1182/blood.v95.12.3702 · Cited by 507
Cited by
Luznik, L., O'Donnell, P. V., Symons, H. J., Chen, A. R., Leffell, M. S., Zahurak, M., Gooley, T. A., Piantadosi, S., Kaup, M., Ambinder, R. F., et al. (2008) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2008.03.005 · Cited by 1,938
Self-citationCiurea, S. O., Zhang, M.-J., Bacigalupo, A. A., Bashey, A., Appelbaum, F. R., Aljitawi, O. S., Armand, P., Antin, J. H., Chen, J., Devine, S. M., et al. (2015) · Blood · doi:10.1182/blood-2015-04-639831 · Cited by 662
Self-citationBashey, A., Zhang, X., Sizemore, C. A., Manion, K., Brown, S., Holland, H. K., Morris, L. E., & Solomon, S. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.3523 · Cited by 499
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease
Luznik, L., Bolaños-Meade, J., Zahurak, M., Chen, A. R., Smith, B. D., Brodsky, R., Huff, C. A., Borrello, I., Matsui, W., Powell, J. D., et al. (2010) · Blood · doi:10.1182/blood-2009-11-251595 · Cited by 409
Self-citationLuznik, L., O'Donnell, P. V., & Fuchs, E. J. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.09.005 · Cited by 336
Self-citationModern approaches to HLA-haploidentical blood or marrow transplantation
Kanakry, C. G., Fuchs, E. J., & Luznik, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.128 · Cited by 330
Self-citationTolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
Mapara, M. Y., & Sykes, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.041 · Cited by 325
Association of Foxp3 regulatory gene expression with graft-versus-host disease
Miura, Y., Thoburn, C. J., Bright, E. C., Phelps, M. L., Shin, T., Matsui, E. C., Matsui, W. H., Arai, S., Fuchs, E. J., Vogelsang, G. B., et al. (2004) · Blood · doi:10.1182/blood-2004-03-1040 · Cited by 320
Self-citationKasamon, Y. L., Luznik, L., Leffell, M. S., Kowalski, J., Tsai, H.-L., Bolaños-Meade, J., Morris, L. E., Crilley, P. A., O'Donnell, P. V., Rossiter, N., et al. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.11.011 · Cited by 281
Self-citationKanakry, C. G., O'Donnell, P. V., Furlong, T., de Lima, M. J., Wei, W., Medeot, M., Mielcarek, M., Champlin, R. E., Jones, R. J., Thall, P. F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0625 · Cited by 278
Self-citationBurroughs, L. M., O'Donnell, P. V., Sandmaier, B. M., Storer, B. E., Luznik, L., Symons, H. J., Jones, R. J., Ambinder, R. F., Maris, M. B., Blume, K. G., et al. (2008) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2008.08.014 · Cited by 266
Self-citationFabricius, W. A., & Ramanathan, M. (2016) · Advances in Hematology · doi:10.1155/2016/5726132 · Cited by 46
Metadata
- Authors
- O'Donnell, P. V., Luznik, L., Jones, R. J., Vogelsang, G. B., Leffell, M. S., Phelps, M., Rhubart, P., Cowan, K., Piantadosi, S., & Fuchs, E. J.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2002-07
- Volume
- 8
- Issue
- 7
- Pages
- 377-386
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W2148233118
- Cited by
- 491
- References
- 24
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.